Ambrx Biopharma (NYSE:AMAM) Vs. Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head Survey
Ambrx Biopharma (NYSE:AMAM) Vs. Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head Survey
Ambrx Biopharma (NYSE:AMAM – Get Rating) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
安博士生物醫藥(NYSE：AMAM-GET Rating)和芬內剋制藥(Fennec PharmPharmticals)(納斯達克：FENC-GET Rating)都是小盤醫療公司，但哪隻股票更優越？我們將根據這兩家公司的估值、機構所有權、盈利能力、分析師建議、收益、股息和風險等方面的實力進行比較。
Volatility and Risk
波動性和風險
Ambrx Biopharma has a beta of -2.17, indicating that its share price is 317% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Ambrx Biophma的貝塔係數為-2.17，表明其股價的波動性比標準普爾500指數低317%。相比之下，Fennec PharmPharmticals的貝塔係數為0.03，表明其股價的波動性比標準普爾500指數低97%。
Insider and Institutional Ownership
內部人與機構持股
43.1% of Ambrx Biopharma shares are owned by institutional investors. Comparatively, 43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. 5.1% of Ambrx Biopharma shares are owned by company insiders. Comparatively, 9.4% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ambrx Biophma 43.1%的股份由機構投資者持有。相比之下，Fennec PharmPharmticals 43.3%的股份由機構投資者持有。Ambrx Biophma 5.1%的股份由公司內部人士持有。相比之下，Fennec PharmPharmticals 9.4%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一家公司的長期表現將好於大盤。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Ambrx Biopharma | N/A | N/A | N/A |
| Fennec Pharmaceuticals | N/A | -214.78% | -97.25% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Ambrx Biopma | 不適用 | 不適用 | 不適用 |
| 芬內剋制藥公司 | 不適用 | -214.78% | -97.25% |
Analyst Recommendations
分析師建議
This is a summary of current ratings and price targets for Ambrx Biopharma and Fennec Pharmaceuticals, as provided by MarketBeat.
這是MarketBeat提供的Ambrx Biophma和Fennec PharmPharmticals的當前評級和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ambrx Biopharma | 0 | 1 | 1 | 0 | 2.50 |
| Fennec Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Ambrx Biopma | 0 | 1 | 1 | 0 | 2.50 |
| 芬內剋制藥公司 | 0 | 0 | 5 | 0 | 3.00 |
Ambrx Biopharma presently has a consensus target price of $4.00, indicating a potential upside of 108.33%. Fennec Pharmaceuticals has a consensus target price of $14.83, indicating a potential upside of 49.38%. Given Ambrx Biopharma's higher probable upside, equities research analysts plainly believe Ambrx Biopharma is more favorable than Fennec Pharmaceuticals.
Ambrx Biophma目前的共識目標價為4美元，表明潛在漲幅為108.33%。Fennec PharmPharmticals的共識目標價為14.83美元，表明潛在上行49.38%。考慮到Ambrx Biophma更有可能上行，股票研究分析師顯然認為Ambrx Biophma比Fennec PharmPharmticals更有利。
Earnings & Valuation
收益與估值
This table compares Ambrx Biopharma and Fennec Pharmaceuticals' gross revenue, earnings per share and valuation.
此表比較了Ambrx Biophma和Fennec製藥公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ambrx Biopharma | $7.45 million | 9.95 | -$68.08 million | N/A | N/A |
| Fennec Pharmaceuticals | $170,000.00 | 1,539.79 | -$17.35 million | ($0.82) | -12.11 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Ambrx Biopma | 745萬美元 | 9.95 | -6,808萬元 | 不適用 | 不適用 |
| 芬內剋制藥公司 | $170,000.00 | 1,539.79 | -1,735萬美元 | ($0.82) | -12.11 |
Fennec Pharmaceuticals has lower revenue, but higher earnings than Ambrx Biopharma.
Fennec PharmPharmticals的收入低於Ambrx Biophma，但收益高於Ambrx Biophma。
Summary
摘要
Fennec Pharmaceuticals beats Ambrx Biopharma on 7 of the 11 factors compared between the two stocks.
Fennec PharmPharmticals在兩隻股票比較的11個因素中有7個擊敗了Ambrx Biophma。
About Ambrx Biopharma
關於Ambrx Biophma
(Get Rating)
(獲取評級)
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Ambrx Biophma Inc.是一家臨牀階段的生物製品公司，利用其專有的擴展遺傳密碼技術平臺發現和開發工程精密生物製品。它的主要候選產品是ARX788，這是一種抗HER2抗體-藥物結合物(ADC)，用於治療乳腺癌、胃/胃食道交界處癌症和其他實體腫瘤的各種臨牀試驗，包括正在進行的治療HER2陽性轉移性乳腺癌和胃癌的2/3期臨牀試驗。該公司還在開發兩種早期候選產品，包括ARX517和ARX305。ARX517是一種抗PSMA ADC，處於治療前列腺癌和其他實體腫瘤的第一階段臨牀試驗；ARX305是一種抗CD70 ADC，正在研究治療腎癌和其他癌症的新藥。此外，該公司還在開發針對免疫腫瘤學應用的其他多種候選產品，其中包括ARX822，一種用於癌症臨牀前開發的Fab-小分子雙特異性藥物；以及ARX102，一種免疫腫瘤學IL-2途徑激動劑，通過靶向細胞毒性T細胞上的嗎和伽馬受體來刺激患者自身的免疫系統。Ambrx Biophma Inc.與百時美施貴寶公司、艾伯維公司、百濟神州、中國生物製藥有限公司、NovoCodex和Elanco Animal Health有合作關係。該公司成立於2003年，總部設在加利福尼亞州拉荷亞。
About Fennec Pharmaceuticals
關於Fennec製藥公司
(Get Rating)
(獲取評級)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
生物製藥公司Fennec PharmPharmticals Inc.開發用於美國癌症治療的候選產品。它的主要候選產品是硫代硫酸鈉，已經完成了預防順鉑引起的兒童聽力損失或耳毒性的第三階段臨牀試驗。該公司前身為Adherex Technologies Inc.，2014年9月更名為Fennec PharmPharmticals Inc.。Fennec製藥公司成立於1996年，總部設在北卡羅來納州的研究三角公園。
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Ambrx Biophma Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ambrx Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。